Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada

被引:836
作者
Chen, DK
McGeer, A
de Azavedo, JC
Low, DE
机构
[1] Mt Sinai Hosp, Dept Microbiol, Toronto, ON M5G 1X5, Canada
[2] Toronto Hosp, Dept Microbiol, Toronto, ON M5T 2S8, Canada
[3] Univ Toronto, Dept Med, Toronto, ON, Canada
[4] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada
关键词
D O I
10.1056/NEJM199907223410403
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Background Fluoroquinolones are now recommended for the treatment of respiratory tract infections due to Streptococcus pneumoniae, particularly when the isolates are resistant to beta-lactam antibiotics. Although pneumococci with reduced susceptibility to fluoroquinolones have been identified, their prevalence has not been determined in a defined population. Methods We performed susceptibility testing on 7551 isolates of S. pneumoniae obtained from surveillance in Canada in 1988 and from 1993 to 1998. Pneumococci with reduced susceptibility to fluoroquinolones (defined as a minimal inhibitory concentration of ciprofloxacin of at least 4 mu g per milliliter) were further characterized. We also examined antibiotic prescriptions dispensed in Canadian retail pharmacies, Results Between 1988 and 1997 fluoroquinolone prescriptions increased from 0.8 to 5.5 per 100 persons per year. The prevalence of pneumococci with reduced susceptibility to fluoroquinolones increased from 0 percent in 1993 to 1.7 percent in 1997 and 1998 (P=0.01). Among adults, the prevalence increased from 1.5 percent in 1993 and 1994 combined to 2.9 percent in 1997 and 1998 combined. The prevalence was higher in isolates from older patients (2.6 percent among those 65 years of age or older vs. 1.0 percent among those 15 to 64 years of age, P<0.001) and among those from Ontario (1.5 percent, vs. 0.4 percent among those from the rest of Canada; P<0.001). Fluoroquinolone use was greatest among the elderly and in Ontario, The 75 isolates (17 serotypes) of pneumococci with reduced susceptibility to fluoroquinolones were submitted by 40 laboratories in eight provinces. Reduced susceptibility to fluoroquinolones was associated with resistance to penicillin. Conclusions The prevalence of pneumococci with reduced susceptibility to fluoroquinolones is increasing in Canada, probably as a result of selective pressure from the increased use of fluoroquinolones, (N Engl J Med 1999;341:233-9.) (C) 1999 Massachusetts Medical Society.
引用
收藏
页码:233 / 239
页数:7
相关论文
共 51 条
[1]
Arason VA, 1996, BMJ-BRIT MED J, V313, P387
[2]
Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA [J].
Ballow, CH ;
Jones, RN ;
Johnson, DM ;
Deinhart, JA ;
Schentag, JJ ;
Tritsch, M ;
Ellis, S ;
Burger, J ;
Cole, E ;
Venezia, R ;
George, M ;
Wolf, D ;
Slifkin, M ;
DePalma, J ;
Rudrik, J ;
Sullivan, K ;
Lewis, G ;
Dooley, G ;
Sawicki, R ;
Desiderio, D ;
Louma, R ;
Motyl, M ;
Ruffin, L ;
Torresan, J ;
Dunaway, G ;
Keck, G ;
Truitt, L ;
Brecher, S ;
VanEnk, R ;
Whelen, C ;
Fader, R ;
Whisler, G ;
Jenkins, S ;
Thacker, D ;
DAmato, R ;
Buck, R ;
Buescher, S ;
Lambert, K ;
Tristram, D ;
Kehl, S ;
Lawson, C ;
Washington, J ;
Robertson, K ;
Beall, A ;
Padgett, L ;
Rahman, L ;
Riddle, G ;
DellaLatta, P ;
Marcon, M ;
Northern, I .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1997, 29 (03) :173-186
[3]
In-vitro susceptibility of Streptococcus pneumoniae to the d- and l-isomers of ofloxacin: Interpretive criteria and quality control limits [J].
Barry, AL ;
Fuchs, PC ;
Allen, SD ;
Brown, SD ;
Jorgensen, JH ;
Tenover, FC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1996, 37 (02) :365-369
[4]
Community-acquired pneumonia in adults: Guidelines for management [J].
Bartlett, JG ;
Breiman, RF ;
Mandell, LA ;
File, TM .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (04) :811-838
[6]
The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: An update from the centers for disease control and prevention's pneumococcal sentinel surveillance system [J].
Butler, JC ;
Hofmann, J ;
Cetron, MS ;
Elliott, JA ;
Facklam, RR ;
Breiman, RF ;
Camp, C ;
Charache, P ;
Dern, R ;
Jackson, M ;
Hadley, WK ;
HoppeBauer, J ;
Jacobs, MR ;
Schreiber, J ;
Boxerbaum, B ;
Menuey, BC ;
Tyler, PG ;
Monahan, J ;
Moore, H ;
Siegel, JD ;
Sherer, D ;
Rogers, P ;
Welch, D ;
Fine, D ;
Radike, J ;
Fiore, A ;
Alexander, M ;
Deaver, K .
JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (05) :986-993
[8]
Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis [J].
Chodosh, S ;
Schreurs, A ;
Siami, G ;
Barkman, HW ;
Anzueto, A ;
Shan, M ;
Moesker, H ;
Stack, T ;
Kowalsky, S .
CLINICAL INFECTIOUS DISEASES, 1998, 27 (04) :730-738
[9]
Multiply antibiotic-resistant Streptococcus pneumoniae recovered from Spanish hospitals (1988-1994): Novel major clones of serotypes 14, 19F and 15F [J].
Coffey, TJ ;
Berron, S ;
Daniels, M ;
GarciaLeoni, ME ;
Cercenado, E ;
Bouza, E ;
Fenoll, A ;
Spratt, BG .
MICROBIOLOGY-UK, 1996, 142 :2747-2757
[10]
DALHOFF A, 1998, 8 INT C INF DIS BOST, P124